Category: Pharma, Life Sciences & Med Tech Players
-
FTC urges Fourth Circuit to reject Amgen plea to shield Roche patent acquisition: deal “threatens to upend” long-settled antitrust framework
The U.S. Federal Trade Commission has filed an amicus brief in an antitrust case between CareFirst and Amgen, urging the Fourth Circuit to reject Amgen’s bid to shield its acquisition of pending patent applications from antitrust scrutiny, as such procurements violate the Sherman Act and are not immunized by the Noerr-Pennington doctrine.
-
UPC Court of Appeal upholds Abbott’s glucose sensor patent: rejects Sibio’s added matter, inventive step attacks
The UPC Court of Appeal has dismissed Sibio’s bid to revoke Abbott’s continuous glucose monitor patent, confirming its own earlier finding from a related injunction case and issuing two headnotes that will guide how the court treats omitted features in future added matter disputes.
-
China’s top court overturns Nefecon generic PI despite U.S. Paragraph III-style no-launch pledgeÂ
A Chinese generic of Nefecon obtained formal approval after promising not to launch until patent expiry, then used that approval to seek procurement listings. China’s top court nevertheless held that the broken Paragraph III-style pledge was a regulatory breach – not an admission of patent infringement.
-
EWHC hinders Accord’s plans to launch Entresto competing product in Novartis patent dispute
Mr. Justice Meade of the High Court of Justice for England & Wales has held that all of Accord’s “attacks” on a Novartis Entresto patent have failed, and its own intended competing product would infringe the defendant’s supplementary protection certificate.
-
UPC Munich LD flags novel questions on damages law in Edwards v. Meril damages claim, flags novel questions on applicable law and non-infringing substitute profits
At an interim hearing, the Munich LD set Edwards’ damages claim against Meril at a €15 million value in dispute and previewed how it may rule on two open legal questions.
-
Patent Litigation Europe returns for 2027, building on last year’s rebrand into three co-located tracksÂ
Speakers already confirmed for the event include Hon. Emmanuel Gouge and Aleš Zalar of the UPC, Judge Oliver Schön of the Munich Regional Court, Abbott’s Gael Tisack, Ericsson’s Gabriele Mohsler, Nokia’s Clemens Heusch, and SIM IP’s Erich Spangenberg.
-
China’s top court hands U.S. patentee landmark patent damages award
U.S. insecticide producer FMC Agriculture Singapore has been awarded a record of nearly 33 million Chinese yuan ($4.84 million) in patent infringement damages in a decision in which the defendant’s legal representative has also been found jointly liable – a rarity in Chinese IP infringement cases.
-
U.S. GLP-1 patent docket grows with raft of new complaints from Eli Lilly, Novo Nordisk
This could well be the start of a wide-ranging, multi-jurisdictional campaign by Eli Lilly to defend its rights around Mounjaro and Zepbound.
-
10x Genomics accused of infringing sequencing patents by Caltech and exclusive licensee
10x is no stranger to enforcing its own sequencing patents, but Spatial Genomics’ District of Delaware complaint sees it on the receiving end of an infringement claim.
-
UPC keeps Merz infringement case despite earlier French filing
The UPC’s Paris LD rejected Viatris’ attempt to halt Merz’s infringement action in favor of parallel proceedings before a French national court. The ruling clarifies when earlier national proceedings prevent the UPC from continuing with an infringement action.